Abbott Laboratories (NYSE: ABT) delivered its third-quarter earnings report on Oct. 21. The stock dropped about 4% in early trading, as the results were merely solid, at a time when investors wanted something spectacular.
Revenue of $13.01 billion edged out expectations for $12.99 billion. Sales rose 14.5% on a reported basis, boosted by the Exact Sciences acquisition, and 7% on a comparable basis, which accounts for the acquisition in both periods.
